Skip to main content
. Author manuscript; available in PMC: 2012 Nov 15.
Published in final edited form as: Cancer Cell. 2011 Nov 15;20(5):674–688. doi: 10.1016/j.ccr.2011.10.015

Figure 8. Tigecycline has in vivo anti-leukemia activity in combination with AML agents daunorubicin and cytarabine.

Figure 8

(A) The effect of a 72 hour exposure of TEX and OCI-AML2 cells to different concentrations of tigecycline in combination with daunorubicin or cytarabine on the viability of the cells was measured by MTS assay after 72 hours of incubation. Data were analyzed with Calcusyn software to generate a Combination index versus Fractional effect (cell death) plot showing the effect of the combination of tigecycline with daunorubicin or cytarabine. CI < 1 indicates synergism. (B) Human leukemia (OCI-AML2) cells were injected subcutaneously into the flank of SCID mice. Six days after injection, when tumors were palpable, mice were treated with tigecycline (50 mg/kg daily by i.p. injection) and/or daunorubicin (0.65 mg/kg t.i.w. by i.p. injection) and/or cytarabine (10 mg/kg daily by i.p. injection) or vehicle control (7 mice per treatment group). Another 2 weeks later, mice were sacrificed, tumors excised and the volume and mass of the tumors were measured and mean values determined. The tumor mass and the mean volume are shown. *P < 0.05, ** P < 0.005, as determined by Tukey’s test after One-way ANOVA analysis. Error bars represent mean +/− S.D. See also Figure S6.